Cover Image

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study

Abstract is missing (Short communication)

Saved in:

Bibliographic Details
Main Authors:	Federica Repetto (Author), Gabriele Roccuzzo (Author), Lorenza Burzi (Author), Luca Mastorino (Author), Paolo Dapavo (Author), Pietro Quaglino (Author), Simone Ribero (Author)
Format:	Book
Published:	Medical Journals Sweden, 2023-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
by: Federica Repetto, et al.
Published: (2022)

Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab
by: Anna Schuch, et al.
Published: (2017)

Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab
by: Ian Gorovoy, et al.
Published: (2009)

Real-world drug survival of patients with hidradenitis suppurativa treated with adalimumab
by: Ryan C. Saal, BS, et al.
Published: (2023)

Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study
by: Luigi Gargiulo, et al.
Published: (2024)

Decreased Serum Level of Interleukin-22 Correlates with Hepcidin in Patients with Hidradenitis Suppurativa
by: Malgorzata Ponikowska, et al.
Published: (2021)

A complication in a patient with hidradenitis suppurativa taking adalimumab
by: Olivia D. Perez, BA, et al.
Published: (2022)

Optic neuropathy in a patient treated with adalimumab for hidradenitis suppurativa
by: Sarah Alnaif, BHSc, et al.
Published: (2023)

Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa
by: Fotiadou C, et al.
Published: (2016)

Overexpression of Interleukin-23 and Interleukin-17 in the Lesion of Pemphigus Vulgaris: A Preliminary Study
by: Jixin Xue, et al.
Published: (2014)

Paradoxical Reaction in a Patient with Hidradenitis Suppurativa Undergoing Adalimumab Treatment
by: Soichiro Ikeya, et al.
Published: (2021)

Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data
by: Aikaterini Kyriakou, et al.
Published: (2018)

Adalimumab Experience in the Management of Hidradenitis Suppurativa Burdened with Rapp-Hodgkin Syndrome
by: Nikolay N. Murashkin, et al.
Published: (2023)

A Review of Interleukin-23/Interleukin-17 Inhibitor Exposure during Pregnancy in Patients with Psoriasis
by: Nirali Doshi, et al.
Published: (2024)

Metastatic squamous cell carcinoma in a patient treated with adalimumab for hidradenitis suppurativa
by: Rachel Giesey, BA, et al.
Published: (2017)

Adalimumab for the Treatment of Periodontitis in a 35-Year-Old Woman with Hidradenitis Suppurativa
by: Yiqiu Yao, et al.
Published: (2023)

Hidradenitis Suppurativa: Modern Concepts of Pathogenesis and Therapy; Successful Experience of Adalimumab Therapy
by: M. M. Khobeish, et al.
Published: (2018)

Adalimumab effect on pain in hidradenitis suppurativa patients: systematic review and meta-analysis
by: Aikaterini Tsentemeidou, et al.
Published: (2022)

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis
by: Maryam Shayesteh Alam, MD, FRCPC, FAAD, et al.
Published: (2020)

Adalimumab in the treatment of moderate-severe hidradenitis suppurativa: a cost-effectiveness analysis
by: Sofia Borges, et al.
Published: (2018)

Interleukin-23 and Th17 Cells in the Control of Gut Inflammation
by: Ivan Monteleone, et al.
Published: (2009)

Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa
by: Carlo Alberto Vignoli, et al.
Published: (2023)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
by: Martora F, et al.
Published: (2023)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022)

Interleukin-23 Inhibitors
by: Esra Adışen
Published: (2022)

The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic reviewCapsule Summary
by: Marie Vangilbergen, MD, et al.
Published: (2024)

IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa
by: Dalma Malvaso, et al.
Published: (2023)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
by: Simone Ribero, et al.
Published: (2019)

Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice
by: Roccuzzo G, et al.
Published: (2022)

Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience
by: Andrea Chiricozzi, et al.
Published: (2020)

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study
by: Martora F, et al.
Published: (2024)

Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy
by: Luca Mastorino, et al.
Published: (2022)

Plasma levels of interleukin-17, interleukin-23, and transforming growth factor-β in Sudanese patients with vitiligo: A case-control study
by: Ali Malik Osman, et al.
Published: (2015)

Hidradenitis Suppurativa Online Documents Readability: An Analysis Including 23 European Languages
by: Skrzypczak T, et al.
Published: (2024)

Effect of Narrow Band Ultraviolet B Therapy versus Methotrexate on Serum Levels of Interleukin-17 and Interleukin-23 in Egyptian Patients with Severe Psoriasis
by: Tarek Mahmoud Elghandour, et al.
Published: (2013)

Hidradenitis suppurativa and intimacy
by: G. Jemec, MD, DMedSci
Published: (2018)

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
by: Potestio L, et al.
Published: (2024)

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
by: Nora Koutruba, et al.
Published: (2010)

Cutaneous T-cell Lymphoma Diagnostic and Therapeutic Trends amidst the COVID-19 Pandemic
by: Gabriele Roccuzzo, et al.
Published: (2024)

A Case of Overlapping Clinical Features of Idiopathic Granulomatous Mastitis, Hidradenitis Suppurativa, and Pyoderma Gangrenosum Successfully Treated with Adalimumab
by: Vesna Breznik, et al.
Published: (2022)